A lawsuit alleging that Merck & Co’s osteoporosis drug Fosamax caused jaw damage ended in a mistrial on Friday .
U.S. District Judge John Keenan declared the mistrial two days giving the New York jury considering the case a “cooling off period” in light of supposed acrimony among jurors.
A Merck lawyer on Wednesday referred to an “unsubstantiated claim” of a chair being thrown in the jury room.
Merck faces lawsuits involving almost 900 cases by patients who say the use of Fosamax causes osteonecrosis of the jaw, or the death of jawbone tissue. The trial is Merck’s first over the drug